# Evaluate the Use of [18F]-APN-1607 PET in Subjects With AD-related Cognitive Impairment and Subjects With Normal Cognitive Function

> **NCT07422857** · PHASE3 · RECRUITING · sponsor: **JYAMS PET Research & Development Limited** · enrollment: 316 (estimated)

## Conditions studied

- Subjects With Mild Cognitive Impairment (MCI) of AD, Alzheimer's Disease (AD) Dementia

## Interventions

- **DRUG:** [18F]-APN-1607

## Key facts

- **NCT ID:** NCT07422857
- **Lead sponsor:** JYAMS PET Research & Development Limited
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-01-22
- **Primary completion:** 2026-12-01
- **Final completion:** 2027-02-01
- **Target enrollment:** 316 (ESTIMATED)
- **Last updated:** 2026-02-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07422857

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07422857, "Evaluate the Use of [18F]-APN-1607 PET in Subjects With AD-related Cognitive Impairment and Subjects With Normal Cognitive Function". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT07422857. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*